drugset
drugset / Trial / NCT00434746

Study of the Safety, Tolerability, PK, and PD of ILV-094 Administered IV or SC to Healthy Subjects

NCT00434746 ↗

Phase 1 Completed 56 enrolled Wyeth is now a wholly owned subsidiary of Pfizer
RandomizedSingle-groupDouble-blindTreatment

Summary

The purpose of this study is to assess the safety and tolerability of ascending single IV doses of ILV-094 (an investigational drug) and one SC dose of ILV-094 in healthy subjects.

Timeline

Start
2007-01
Primary completion
2008-02
Completion
2008-02

Drugs

EvaluationDrugModalityDoseRoute
Subject FEZAKINUMAB Monoclonal antibody 5 mg Intravenous
Subject FEZAKINUMAB Monoclonal antibody 15 mg Intravenous
Subject FEZAKINUMAB Monoclonal antibody 50 mg Intravenous
Subject FEZAKINUMAB Monoclonal antibody 100 mg Intravenous
Subject FEZAKINUMAB Monoclonal antibody 300 mg Intravenous
Subject FEZAKINUMAB Monoclonal antibody 600 mg Intravenous

Indications

No indication recorded.